当前位置: 首页 > 期刊 > 《中医药学刊》 > 2012年第4期 > 正文
编号:12209315
参麦注射液联合重组人脑利钠肽治疗急性心力衰竭的临床研究(1)
http://www.100md.com 2012年4月1日 蔡宏文,杨兵生,黄兆铨,毛威
第1页

    参见附件。

     摘 要:目的:观察参麦注射液和重组人脑利钠肽(rhBNP)联用治疗急性心力衰竭(AHF),较之单用rhBNP,其临床症状、血浆脑钠肽(BNP)水平以及肾功能、低血压等指标的变化。方法:将52例AHF患者随机分为两组,对照组在常规治疗的基础上加用rhBNP,治疗组在对照组的基础上加用参麦注射液。观察两组的临床疗效、血浆BNP水平、肾功能和低血压反应的变化,并进行组内和组间的比较。结果:两组在临床疗效上差异无统计学意义(P>0.05),但治疗组的血浆BNP水平较之对照组降低更加显著(P<0.05)。治疗组治疗后的血肌酐水平较治疗前有显著降低(P<0.05),与对照组比较有显著优势(P<0.05)。治疗组低血压发生率明显少于对照组,差异具有统计学意义(P<0.05)。结论:参麦注射液联用rhBNP能进一步增强后者的抗心衰作用,并能避免rhBNP引发的肾功能损害和低血压反应,值得临床推广应用。

    关键词:参麦注射液;重组人脑利钠肽;急性心力衰竭

    中图分类号:R285.6

    文献标识码:B

    文章编号:1673-7717(2012)04-0750-03

    Clinical Study of Shenmai Injection Combined with Recombinant

    Human Brain Natriuretic Peptide Treating Acute Heart Failure

    CAI Hong-wen,YANG Bing-sheng,HUANG Zhao-quan,MAO Wei

    (Department of Cardiology, Zhejiang Hospital of Traditional Chinese Medicine, Hangzhou, 310006, Zhejiang, China)

    Abstract:Objective:To observe the therapeutic efficacy and safety of Shenmai injection combined with recombinant human brain natriuretic peptide(rhBNP) in treating acute heart failure(AHF).Methods:A total of 52 patients of AHF were randomly divided into two groups, the control group received routine therapy combined with rhBNP, the treatment group received the same treatment of control group, while in addition, they received an injection of Shenmai injection simultaneously. The therapeutic efficacy, plasma brain natriuretic peptide(BNP), renal function and hypotension were observed and compared within the group and between groups. Results:There was no significant difference in therapeutic efficacy between the two groups(P>0.05), both plasma levels of BNP were decreased, and the treatment group was better(P<0.05). The serum creatinine level was significantly decreased after therapy in the treatment group than that in the control group(P<0.05). The incidence of hypotension in the treatment group was significantly less than that in the control group, the difference was statistically significant(P<0.05).Conclusion:Shenmai injection can further enhance the therapeutic efficacy of rhBNP and avoid the rhBNP-induced renal dysfunction and hypotension, a combination of the two is worthy of clinical application.

    Key words:Shenmai injection;recombinant human brain natriuretic peptide;acute heart failure ......

您现在查看是摘要介绍页,详见PDF附件(2328kb)